Fig. 6

Creatine is released from activated Pannexin 1 channel of Myo-ApoEVs during C2C12 myoblasts fusion. a, b Heat map (a) and volcano plot (b) of untargeted metabolomics of supernatants from control group or STS-induced apoptotic C2C12 myoblasts group, representing statistically enriched or reduced (P < 0.05) metabolites in the apoptotic supernatant relative to the control supernatant, n = 4 per group. c–f Relative creatine ratio in different treated C2C12 myoblasts groups. Relative creatine change of C2C12 myoblasts supernatants in growth medium (c) or fusion medium (d) over time. Relative creatine change of C2C12 myoblasts supernatants in the STS-induced apoptotic group relative to the control group (e). Relative creatine change of C2C12 myoblasts supernatants in the MSCs-ApoEVs treated group relative to the control group (f). g–l Relative expression and analysis of Pannexin 1 channel protein of control group, 12 h STS-induced group, and Myo-ApoEVs group in whole cell protein lysis or membrane protein lysis. Relative expression of Pannexin 1 channel of different groups in whole cell protein lysis or membrane protein lysis examined by western blot (g, j). Analysis of relative expression of Pannexin 1 protein and cleaved-Pannexin 1 protein of different groups in whole cell protein lysis or membrane protein lysis (h, i, k, l). m Relative creatine change of C2C12 myoblasts supernatants in fusion medium over time with BB-FCF treatment. n = 3 per group; data were shown as mean ± SD; ns, not significant; *P < 0.05; **P < 0.01; ***P < 0.001. BB-FCF, Brilliant Blue FCF